RhumbLine Advisers
AUTL

RhumbLine Advisers’s Autolus Therapeutics AUTL Stock Holding History

RhumbLine Advisers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62K Buy
38,764
+3,813
+11% +$5.98K ﹤0.01% 3644
2026
Q1 		$48.2K Buy
34,951
+2,700
+8% +$4.1K ﹤0.01% 3595
2025
Q4 		$64.2K Buy
32,251
+15,870
+97% +$24.4K ﹤0.01% 3588
2025
Q3 		$26.7K Sell
16,381
-328
-2% -$641 ﹤0.01% 3744
2025
Q2 		$38.1K Buy
16,709
+9,336
+127% +$15.4K ﹤0.01% 3711
2025
Q1 		$11.4K Buy
7,373
+1,033
+16% +$2.1K ﹤0.01% 3813
2024
Q4 		$14.9K Buy
6,340
+233
+4% +$788 ﹤0.01% 3836
2024
Q3 		$22.2K Buy
6,107
+305
+5% +$1.22K ﹤0.01% 3805
2024
Q2 		$20.2K Buy
5,802
+3,488
+151% +$15.1K ﹤0.01% 3873
2024
Q1 		$14.8K Buy
2,314
+1,166
+102% +$7.27K ﹤0.01% 3807
2023
Q4 		$7.39K Hold
1,148
– – ﹤0.01% 3916
2023
Q3 		$2.67K Sell
1,148
-80
-7% -$228 ﹤0.01% 4079
2023
Q2 		$2.92K Buy
+1,228
New +$2.91K ﹤0.01% 4169

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RhumbLine Advisers's AUTL Position: Q2 2026 in Review

RhumbLine Advisers increased its Autolus Therapeutics (AUTL) stake by 11% in Q2 2026, buying an estimated $5.98K and bringing the position to 38,764 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

RhumbLine Advisers first reported a position in AUTL in Q2 2023 and has held it in 13 quarters since. The position peaked at $64.2K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • RhumbLine Advisers held 38,764 shares of Autolus Therapeutics worth $62K as of Q2 2026.
  • RhumbLine Advisers bought 3,813 Autolus Therapeutics shares in Q2 2026, an estimated $5.98K.
  • Autolus Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3644 holding.
  • RhumbLine Advisers first reported a position in Autolus Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Autolus Therapeutics position peaked at $64.2K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.